An observational study in Colorectal Cancer Metastatic, Mismatch Repair Deficiency and Microsatellite Instability High, sponsored by Sun Yat-sen University. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-27.
Sponsored by Sun Yat-sen University · Observational
Among 12 studies in Turcot syndrome with a site in China — 7 open to participants now, 10 under way, none of them phase 3. Turcot syndrome · China.
Among the 12 studies in Turcot syndrome with a site in China, this one is one of 2 that started in 2019, is the only observational one, and was the 2nd registered.
60 studies on the registry are indexed under Turcot syndrome; 29 are open to participants now.
Browse Turcot syndrome studies →7 of the 12 studies in Turcot syndrome with a site in China are open now. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–45 · Women only
Yu jiren · Sites in China
Ages 18–80
West China Hospital · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 19 Turcot syndrome studies recruiting now, 16 (84%) set no upper age limit and 2 (11%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9
First in 2019; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 671 is close to the median of 671 across 13 observational studies indexed under Turcot syndrome.
Median enrollment 28 across the 11 interventional studies, 671 across the 1 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 9 most frequent:
Sun Yat-sen University is the lead sponsor of 1,690 studies on the registry; 618 are open to participants now.
Sun Yat-sen University has 4 studies filed under Turcot syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Turcot syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03926338Sun Yat-sen UniversityNeoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer | 2027-04-01 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Turcot syndrome with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC). The efficacy and survival of patients with dMMR/MSI-H status received palliative chemotherapy have not clear yet. In this study, the investigators observed the efficacy and survival of dMMR/MSI-H status mCRC patients received palliative first-line chemotherapy.
Colorectal cancer (CRC) is the one of most common cancer in the world. Loss of function of DNA mismatch repair (MMR) is an important mechanism of CRC development. Mutation or modification of MMR genes result in MMR protein deficient (dMMR) and microsatellite instability (MSI). It has been reported that the dMMR or MSI high (MSI-H) phenotype is present in approximately 15-18% of CRC patients. Most dMMR/MSI-H tumors are sporadic CRC, and only approximately 3% of dMMR/MSI-H tumors are Lynch syndrome (LS) or hereditary nonpolyposis colorectal carcinoma (HNPCC).
The dMMR/MSI-H status was reported to be a predictive marker for adjuvant chemotherapy. Multiple retrospective studies showed that dMMR/MSI-H is correlated with a favorable prognosis in stage II/III CRC. Previous studies suggested that dMMR/MSI status may be a predictive marker of decreased benefit form adjuvant monotherapy of 5-fluorouracil (5-FU) in patients with stage II disease, but not in those with stage III disease. For metastatic colorectal cancer (mCRC), the relationship of the MMR/MSI phenotype and prognosis is unclear. Some researchers found that CRC patients with the dMMR/MSI-H phenotype have a worse prognosis. But other researchers thought the dMMR/MSI-H phenotype is no associate to efficacy and survival of palliative chemotherapy, even is benefit for efficacy and survival.Therefore, the aim of this study was to clarify whether the status of dMMR/MSI-H affected progression-free survival (PFS) in mCRC patients who received first-line palliative chemotherapy.
The metastatic colorectal patients with different MMR or microsatellite status received palliative chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The metastatic colorectal cancer patients with proficient mismatch repair or microsatellite stable status.
The metastatic colorectal cancer patients with deficient mismatch repair or microsatellite instability high status.
Progression-Free Survival (PFS)
PFS as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Time frame: up to 24-36 months
Response rate
Based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Time frame: From first patient first visit to 6 month after last patient first visit
Disease Control Rate (DCR)
Based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Time frame: From first patient first visit to 6 month after last patient first visit
Overall survival
The time from registration to death due to any cause, or censored at date last known alive.
Time frame: up to approximately 9 year
Ran from Sep 2019 to primary completion in Apr 2020, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.